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Abstract 
The rise in the number of musculoskeletal disorders (MSDs) due to an increasingly aging 
population has led to a growing demand for medication to prevent and treat these diseases. An 
increased interest in the development of new drugs to allow treatment of these diseases in 
their very early stages is currently observed. The current approach on local direct delivery of 
medication and key minerals to support bone repair and regeneration at the defect site, from 
flexible degradable devices, seems to be an effective strategy. Polylactic acid (PLA) and 
microspheres of hydrothermally converted coralline hydroxyapatite (cHAp) were used to 
develop PLA thin film composites as drug delivery systems. The PLA provided flexibility 
and biodegradability of the systems, while coralline hydroxyapatite provided the required 
calcium and phosphate ions for bone regeneration. These coralline hydroxyapatite 
microspheres have a unique architecture of interconnected porosity, are bioactive in nature 
and suitable for drug loading and controlled slow drug release. The cell attachment and 
morphology of the PLA thin film composites were evaluated in vitro using cell cultures of 
human adipose derived stem cells (hADSC). It was shown that hADSC cells exhibited a 
strong attachment and proliferation on PLA thin film-cHAp composites, signifying high 
biocompatibility and a potential for osteointegration due to the presence of HAp.  
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Introduction 
Different types of cells have been used in tissue engineering and in therapeutic strategies in 
cell therapy, including stem cell transplantation. Stem cells are primarily used to understand 
the mechanisms by which natural or synthetic biomaterials are able to elicit a cellular 
response when implanted in vivo. In the early days, adult stem cells were used in this process 
but proved difficult to grow in culture because they were fully developed [1]. Attention was 
later focused onto the use of fetal cells, which are not stem cells but behaved similarly and 
better than adult cells when tested in conjunction with biomaterials [1, 2].   
 Stem cells are capable of continuous self-renewal for an extended period of time with 
minimal phenotypic changes. They are also unspecialized and can be differentiated into 
mature functional cells in any of the dermal linages. The two most widely utilized adult stem 
cells are derived from bone marrow extracts and adipose lipoaspirates and are termed as bone 
marrow stem cells (BMSCs) and adipose derived stem cells (hADSCs), respectively. BMSCs 
are involved in repair mechanisms during injury and have been extensively investigated, 
specifically in orthopaedic applications.  
 
Biocompatibility of biomaterials involves three important stages: adhesion of cells on the 
surface, proliferation and finally, differentiation. When a biomaterial is implanted into a 
living body, the biomaterial is rapidly coated with a protein layer before the cells’ attachment. 
Serum protein and various extracellular matrices (ECM) are involved, such as fibronectin, 
fibrinogen, albumin and vitronectin [3]. The protein adsorption and conformation is mainly 
influenced by the morphology of the biomaterial surface, which also influences the cell 
adhesion and proliferation process [4]. It has been reported that micro/nano surface 
topography has a direct impact on cell adhesion and proliferation, with a micro and nano-
textured surface favouring adhesion. 
 
Apart from the morphology, the surface charge and chemical composition of the biomaterial 
surface has been suggested to play a significant role in the adhesion and proliferation of cells. 
Keselowsky et al. [5] showed that cell adhesion through the integrin group of cell surface 
receptors, depends on the conformation of adsorbed fibronectin. In their demonstration, they 
used a self-assembly monolayer of different functional groups such as -OH, -COOH, -NH2 
and -CH3 termini, to create surfaces with different chemistry that were hydrophilic and 
neutrally charged; hydrophilic and acidic; hydrophilic and basic; and hydrophobic, 
respectively. Their findings suggested that the adhesion strength of cell binding (as 
determined by a centrifugation assay) followed the trend: -OH>-COOH>-NH2>-CH3. They 
also found that the specific gene expression of cells such as osteoblast, alkaline phosphatase 
enzyme activity and matrix mineralization, showed dependence on surface chemistry in 
which -OH and -NH2 terminated surfaces were more advantageous, compared with -COOH 
and -CH3. Hydrophobic surfaces seem to cause denaturation of proteins and prevent the 
surface exposure to cell-binding groups responsible to cell adhesion. On the other hand, 
hydrophilic and neutrally charged surfaces induce the least extent of unfolding or 
denaturation, leading to a good cell adhesion on the fibronectin [6].  
 
It has been reported that calcium phosphate bone substitutes derived from mixed 
hydroxyapatite (HAp) and β-tricalcium phosphate (β-TCP) are one of the most promising 
materials for bone drug delivery systems. Major attention has been focused on the delivery of 
antibiotics, due to their wide areas of application as prevention against infection during 
surgical interventions, or in general in the treatment of bone related infections [7].  
 
For slow drug delivery applications, ceramics and other materials such as polymers and 
biocomposites have been proposed in the past, but they are difficult to form into an 
appropriate shape with adequate interconnected micro porosity in order to be fitted into any 
type and size of bone defect. The treatment of bone infection remains difficult because of 
problems with the local penetration of systemically administered antibiotics. Recently, Chu et 
al. demonstrated that marine shells with specific micro spherical design offer desired 
functions for the delivery of bisphosphonate (paminodrate) and an antibiotic (gentamicin) [8]. 
This has been possible by virtue of their unique structure and the architecture of the 
foraminifera shells, which are extraordinarily difficult to manufacture currently [9, 10].  
 
In this paper, polylactic acid (PLA) and microspheres of hydrothermally converted coralline 
hydroxyapatite (cHAp) were used to develop PLA thin film composites as drug delivery 
systems. PLA provided flexibility and biodegradability; whereas cHAp provided bioactivity 
and osteoconductivity. The cell attachment and cell morphology on PLA thin film composites 
were evaluated in vitro using cultures of human adipose derived stem cells (hADSC).  
 
Materials and Methods 
Coral skeleton samples were obtained from the Great Barrier Reef, QLD Australia; 
gentamicin sulfate, clodronate (dichloromethylenediphosphonic acid disodium salt), 
chloroform diammonium hydrogen phosphate (NH4)2HPO4, 98%), and sodium hypochlorite 
(NaClO) were obtained from Sigma Aldrich, Castle Hill, Australia. The PLA was purchased 
from NatureWorks Australia. 
 
 
Porosity measurement 
Porosity measurements were carried out with a mercury intrusion porosimeter (Autopore III, 
Micromeritics Instruments Inc., Norcross, GA, USA) with a 5-cm3 powder penetrometer. 
PLA thin film composites and drug loading 
Hydrothermally converted coralline hydroxyapatite particles were loaded with 10% w/w of 
gentamicin as described in previous works [7, 11]. The required amount of gentamicin was 
dissolved in polished 18 MΩ water (MilliQ, Millipore, Victoria, Australia), mixed with HAp, 
sonicated and then dried using a Rotavapor R-210 coupled with a V-850, BUCHI (In vitro 
Technologies, Australia, vacuum controller) at 60 oC. Gentamicin-loaded cHAp microspheres 
were then dried in vacuumed desiccators and used to produce PLA thin film composites. 
Drug loading of the PLA films was performed as described by Macha et al. [12] by adding the 
required amount of gentamicin or gentamicin-loaded cHAp into PLA chloroform solution to 
give 10% (w/w) drug in the composites under magnetic stirring, followed by sonication to 
break down the agglomerations of particles, cast in Petri dishes and then dried in a desiccator 
under vacuum to produce transparent pore-free thin films. The films thickness were measured 
to be in the range 0.1 – 0.2 mm. 
 
The samples for the stem cell experiments were cast into sterilized glass Petri dishes 60 x 15 
mm. Before cell seeding, the samples were sterilized in UV for 40 minutes. 
 
Antibacterial efficacy test was performed and presented in our previosly work [13]. Briefly, 
an antimicrobial efficacy test was conducted in Tryptone Soya Broth (TSB). Inoculum 
density equivalent to 0.5 McFarland standards (1 x 108 CFU/ml) from overnight culture, with 
a 50 ml TSB sub-culture was used. PLA film composites loaded with gentamicin were either 
introduced in the beginning or after 90 minutes of bacterial growth in a dry incubator at 37 ± 
0.1 oC, with shaking at 220 rpm. The optical density of the culture was monitored by 
spectrophotometer at 595 nm from the experiment at time 0, which was immediately after 
introduction of gentamicin loaded PLA films, and every half an hour for the first 6 to 6.5 hrs. 
When OD reaches about 1, samples were diluted to 1:10 before measurement. An additional 
time-point was obtained after 24 hrs to check for recovery. Replicates of all experiments were 
done in different days.  
 
Cell culture experiment 
Human ADSCs were collected and used under University of Technology Sydney (UTS) 
2013000437-Santos and 2015000118-Santos ethics project approvals. The hADSCs were 
sourced and cultured as per Santos et al., (Submitted,Stem Cell International). The cell 
attachment and morphology were evaluated in vitro using cultures of human adipose derived 
stem cells (hADSC) at passage 5 in biological triplicates. Approximately 5 x 104 cells/ml 
were seeded on glass Petri dishes with the cast samples in DMEM/F12 Glutmax (Gibco) 10 
% fetal bovine serum (Gibco) and incubated at 37°C, 5% CO2 for 7 days. Briefly, the PLA 
and PLAGM samples were coated with poly-L-lysine at room temperature for 30 minutes and 
rinsed twice with phosphate buffered saline (pH 7.4) before cell culture. Samples were 
washed with PBS (pH 7.4), fixed in 4% formaldehyde (Sigma) and then dehydrated in an 
ethanol gradient from 10%-100% at 10% increments at 10 minutes each, before the cells were 
observed in SEM (ZEISS Supra55VP, Zeiss, Germany) operated at 5kV accelerated voltage, 
using a back scatter electron detector.  
 
 
 
 
Results and Discussions 
Figure 1 shows the morphology of coralline materials hydrothermally converted to 
hydroxyapatite in a phosphate solution. Figure 1a suggests that HAp retained the morphology 
of the original coral after conversion.  
 
 Figure 1: SEM picture of (a) coral solid piece showing the retained porous morphology after 
conversion, b) coral solid piece before conversion for comparison, c) coralline piece after 
conversion to hydroxyapatite, d) converted coral piece showing platelets/needle-like 
morphology of hydroxyapatite. 
 
Figure 1d also shows coral after conversion, revealing the hydroxyapatite platelet/needle-like 
morphology. After ball milling coralline particles still contain meso and nanopores for drug 
loading and release. The porosity analysis of coral powder (Figure 2), shows the pore sizes in 
the range of 3 nm - ~350 μm. It was also indicated that most of the crushed and ground 
particles have pore sizes around 4.5 μm with a surface area determined to be 3.23 m2/g. The 
porosity of coral particles was determined to be 58% in the size range considered (3 nm-350 
nm). The results are consistent with results reported previously, using Nuclear Magnetic 
Resonance (NMR) [14]. 
 Figure 2: Porosity within (a) coral powder; pore size and pore size distribution and b) coral; 
evidence of pre-existing nanopores in a solid piece of coral. 
 
 Figure 3: Hydrothermally coral-converted HAp (a) before gentamicin loading and (b) after 
gentamicin loading. 
 
Scanning electron microscopy (SEM) was used to confirm the physical presence of loaded 
drugs in HAp particles as shown in Figure 3. FTIR was used in previous work to evaluate any 
alteration of drugs loaded in a PLA matrix [7]. Figure 3 shows micrographs of HAp before 
(Figure 3a) and after loading with gentamicin (Figure 3b). It is evident that converted coral 
particles are coated with the drug on the surface and into the micro, meso and nanopores, as 
the drug solution could easily penetrate into these pores.  
 Figure 4: SEM image of hADSCs cultured PLA thin film composites for 10 days, showing 
attachment and morphology of cells. The controls are presented on left hand column of media 
and films of PLA, PLAGM, PLAHAp and PLAHApGM with no cells. These are clear and 
devoid of cells. The column on the right are the films PLA, PLAGM, PLAHAp and 
PLAHApGM incubated with the cells. The image results show no cellular attachment of 
hADSCs to PLA or PLAGM with some precipitate forming on the latter. The final two 
images exhibit a highly confluent layer of attached homogenous hADSCs are present across 
the films PLAHAp and PLAHApGM. 
 Synthetic polymeric biomaterials can only support cell adhesion and proliferation to a limited 
extent due to the lack of functional groups necessary for cell interaction [15]. Figure 4 
presents SEM images showing the morphology and attachment of hADSC seeded on PLA 
thin film composites. The results show abundant cell attachment on PLAHAp and 
PLAHApGM samples, but no cell attachment on PLA and PLAGM.  
 
PLA has an alkyl pendant group (CH3-) in its backbone, which makes the polymer more 
hydrophobic and tends to denaturalize proteins responsible for cell binding and adhesion. 
Gentamicin has -NH2 groups, which with the -CH3 groups on the polymer backbone, reduce 
any chance for protein binding on the surface. This was evident because PLA and PLGM 
samples do not show any cells on their surfaces. The addition of hydroxyapatite (HAp) in the 
matrix results in an improvement of bioactivity of composite films by changing the surface 
chemistry from hydrophobic to hydrophilic. The presence of –OH groups due to HAp on the 
other hand, favours the binding of adhesive proteins such as vitronectin and fibronectin and 
subsequently cellular interaction [16]. There are several methods currently used to treat 
biomaterial surfaces in order to improve their biocompatibility, including physical, chemical 
and mechanical treatments. Surface treatments such as exposure to plasma, formation of 
coatings, corona discharge, implantation of ions and ultraviolet (UV)-ozone treatments can 
enhance cell attachment. Specific functional groups can be also covalently attached to 
biomaterial surfaces using chemical modification methods, to attach for example 
biomolecules [3]. 
 
 Figure 5: SEM micrographs of cell cultured samples coated with poly-L-lysine a) PLA b) 
PLAGM 
 
In order to confirm the lack of protein adsorption on the surface of the PLA and PLAGM 
samples, they were coated with poly-L-lysine as an attachment factor to enhance the 
electrostatic interactions between negatively charged ions of the cell membrane and positively 
charged ions of the culture surface, by increasing the number of positively charged sites 
available for cell binding. The results suggest that cells were able to attach on the PLA and 
PLAGM surfaces after coating with poly-L-lysine in less than 24 hours as shown in Figure 5.  
 
Conclusions 
The study of PLA–calcium phosphate thin film composites reveals possible potential 
applications of these devices as drug delivery systems in the biomedical field. The flexibility 
they provide allows them to conform to any desired clinical shape and size. Incorporation of 
hydroxyapatite in the matrix has the added advantage of improving bioactivity and the 
continuous supply of calcium Ca2+ and phosphate PO43- ions which can assist in bone 
regeneration and repair. On one hand, PLAHAp and PLAHApGM display a strong affinity to 
hADSC, due to the presence of HAp in the polymeric matrix. On the other hand, a lack of cell 
attachment on the PLA and PLAGM could be observed. Coating PLA and PLAGM surfaces 
with poly-L-lysine reveals the possibility of surface treatments that can enhance cell 
attachment, which could be of medical importance. Although, not carried out here, possibly 
other surface methods like plasma treatments could also be employed to render the surfaces 
suitable for protein binding. The use of PLA-HAp composites as drug release systems with 
excellent biocompatibility could pave the way for  a new generation of drug delivery systems 
for bone regeneration. 
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